Replies to post #376742 on Amarin Corp Plc (AMRN)

[ziploc_1]

KM became CEO in Q3, 2021 and instituted a necessary rebate system in Q4, 2021...Until then, Amarin was like a deer in the headlites....Up to that time, the most pertinent reactions from management to the Du decision were for the COB to sell all the Amarin stock in the Sofinnova fund, where he was managing director...and decline to support EPADI in their appeal....IMO because it would embarrass his friends at Covington.

KM had been appointed CEO only a short time before the EPADI appeal and had little clout to convince Ekman to back the EPADI appeal.

Since he became CEO, KM has been running Amarin again like a business rather than a sinecure.

.

[Whalatane]

Re EU / UK pricing . I expect all these countries will eventually only accept a price below $200 a month
It will surprise me if Germany pays a higher price then Sweden given the size of their market and the economic headwinds their economy faces ...
Re Formularies ...yes I had looked at several ...and looking at the 5 largest in more detail ...I'm only seeing Aetna ( Tier 4 ) and Cigna ( Tier 3 ) with KM's vaunted " exclusivity ".

AMRN has to adjust to the new reality ....insurers will demand and will receive lower prices from AMRN . They need to cut expenses to reduce cash burn

Kiwi